- Home
- ALT vs KOD Comparison
ALT vs KOD Comparison
Compare ALT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- KOD
- Stock Information
- Founded
- ALT 1997
- KOD 2009
- Country
- ALT United States
- KOD United States
- Employees
- ALT N/A
- KOD N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALT Health Care
- KOD Health Care
- Exchange
- ALT Nasdaq
- KOD Nasdaq
- Market Cap
- ALT 397.4M
- KOD 198.4M
- IPO Year
- ALT N/A
- KOD 2018
- Fundamental
- Price
- ALT $4.21
- KOD $5.17
- Analyst Decision
- ALT Strong Buy
- KOD Hold
- Analyst Count
- ALT 6
- KOD 3
- Target Price
- ALT $18.20
- KOD $9.00
- AVG Volume (30 Days)
- ALT 11.4M
- KOD 312.0K
- Earning Date
- ALT 08-07-2025
- KOD 08-13-2025
- Dividend Yield
- ALT N/A
- KOD N/A
- EPS Growth
- ALT N/A
- KOD N/A
- EPS
- ALT N/A
- KOD N/A
- Revenue
- ALT $20,000.00
- KOD N/A
- Revenue This Year
- ALT N/A
- KOD N/A
- Revenue Next Year
- ALT $1,557,547.90
- KOD N/A
- P/E Ratio
- ALT N/A
- KOD N/A
- Revenue Growth
- ALT N/A
- KOD N/A
- 52 Week Low
- ALT $2.90
- KOD $1.92
- 52 Week High
- ALT $11.16
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ALT 39.67
- KOD 74.91
- Support Level
- ALT $4.33
- KOD $3.70
- Resistance Level
- ALT $4.79
- KOD $4.01
- Average True Range (ATR)
- ALT 0.52
- KOD 0.29
- MACD
- ALT -0.16
- KOD 0.13
- Stochastic Oscillator
- ALT 26.92
- KOD 98.18
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.